Merck & Co. (MRK): Strong Growth Driven by Keytruda and New Vaccine Approvals

Published on 18 Oct 2024 on Insider Monkey · via Yahoo Finance

Merck & Co. (MRK): Strong Growth Driven by Keytruda and New Vaccine Approvals

We recently published a list of 10 Best Medical Stocks to Buy Now. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other best medical stocks to buy now.

Navigating the Healthcare Landscape: Investment Opportunities and Growth Trends

The medical and healthcare industry is one of the largest globally, with a steady demand for products and services due to the biological nature of humans. Stocks like Pfizer Inc. (NYSE:PFE) and Tenet Healthcare Corporation (NYSE:THC) are among the biggest in the world, benefiting from trends that arise during crises like the coronavirus pandemic. Following the pandemic’s rapid spread in 2020, investors were eager to identify the best medical stocks to navigate the global healthcare crisis.

News

Merck & Co. (MRK): Strong Growth Driven by Keytruda and New Vaccine Approvals

NYSE.PFE price evolution

PAR.MRK price evolution

Want to become a better investor?

Merck earnings top estimates amid solid demand for Keytruda cancer drug By...

Will Merck's Guidance Cut Prove Gruesome For Shares?

Merck’s Q3 earnings beat estimates, but company lowers guidance

Merck Narrows Sales Outlook With Gardasil Shot Lagging in China

Merck tops earnings estimates on strong demand for Keytruda, new drugs even as...

Merck & Co., Inc. (MRK): A Bull Case Theory

Jim Cramer Thinks That Merck & Co., Inc. (MRK) Is ‘Too Low’

Snow probes adapted to improve pharmaceutical manufacturing | Cornell Chronicle

Analysts hail Vera's kidney drug as potential 'functional cure' as benefits...

Why Is Moderna Stock Trading Higher On Monday?